Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | HCRTR1 | O43613 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 0.80 |
| ▸ | GLA | P06280 | 4/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.80 |
| ▸ | PPARG | P37231 | 1/20 | 0.80 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.80 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30504076 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL30466257 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL29576858 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL1347142 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL4799251 | 0.87 | KDM4E (0.77) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL24140789 | 0.86 | KDM4E (0.76) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL796265 | 0.85 | MAPT (0.74) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL2136609 | 0.84 | MAPT (0.73) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL4800801 | 0.84 | SMN1; SMN2 (0.90) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 | |
| SCHEMBL30884120 | 0.84 | KDM4E (0.72) | SMN1; SMN2MAPTKDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012108689-A2 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | 부산대학교 산학협력단 (KR) | 2012-08-16 | — | — | WO | claimed |
| US-10005744-B2 | Compounds for the treatment or prevention of breast cancer | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2018-06-26 | — | — | US | disclosed |
| US-20180134673-A1 | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF BREAST CANCER | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
| EP-3296294-A1 | COMPOUND FOR TREATING OR PREVENTING BREAST CANCER | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd (CN) | 2018-03-21 | — | — | EP | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20150366776-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NAT UNIV IND COOP FOUND (KR) | 2015-12-24 | — | — | US | disclosed |
| US-9155690-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2015-10-13 | — | — | US | disclosed |
| US-8889881-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor | Pusan National University Industry —University Cooperation Foundation (KR) | 2014-11-18 | — | — | US | disclosed |
| US-20140037564-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | Pusan National University Indusrtyuniversity (KR) | 2014-02-06 | — | — | US | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| WO-2012104875-A1 | BENZOTHIAZOLE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-08-09 | — | — | WO | disclosed |
| CN-101420950-B | Treatment of duchenne muscular dystrophy | SUMMIT CORP PLC | 2012-04-18 | — | — | CN | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2218464-A1 | Compounds for non-invasive measurement of aggregates of amyloid peptides | Technische Universität München (DE) | 2010-08-18 | — | — | EP | disclosed |
| CN-101678107-A | Pharmaceutical composition for treating Duchenne muscular dystrophy | SUMMIT CORP PLC | 2010-03-24 | — | — | CN | disclosed |
| CN-101420950-A | Treatment of Duchenne muscular dystrophy | SUMMIT CORP PLC (GB) | 2009-04-29 | — | — | CN | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| US-20070154732-A1 | Dendrimer compound and organic luminescent device employing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366776-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PPARG, PPARA, TYR | SMN1; SMN2 3671/4885MAPT 1956/4885KDM4E 3430/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | SMN1; SMN2 4/4885MAPT 3113/4885KDM4E 3311/4885 |
| US-10005744-B2 | Compounds for the treatment or prevention of breast cancer | BRCA1, CYP19A1, PGR | SMN1; SMN2 3153/4885MAPT 4167/4885KDM4E 287/4885 |
| US-20140037564-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR | PPARG, PPARA, PPARD | SMN1; SMN2 4087/4885MAPT 2700/4885KDM4E 3588/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | SMN1; SMN2 9/4885MAPT 4858/4885KDM4E 2080/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | SMN1; SMN2 9/4885MAPT 4858/4885KDM4E 2080/4885 |
| US-20180134673-A1 | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF BREAST CANCER | BRCA1, CYP19A1, PGR | SMN1; SMN2 3153/4885MAPT 4167/4885KDM4E 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.